Sotio Biotech has advanced its effort to become a major player in the solid tumor space. Days after raising $316 million, Sotio has unveiled a deal with Merck to use Keytruda in a clinical trial that is central to its plans for investing in the megaround. 

MeiraGTx has announced preliminary data from the ongoing Phase 1 AQUAx trial of AAV-hAQP1 for grade 2/3 radiation-induced xerostomia (RIX).

Cerevance is working to change that. Proprietary
technology that accurately determines brain age and
relates it to Alzheimer’s, Parkinson’s, and other brain
diseases is providing novel insights that inform therapeutic development

Durect focuses on eliminating the epigenetic faults that cause cells to become dysfunctional. Following this approach, Durect intends to generate drugs that can treat acute organ injury and chronic liver diseases.

Sotio is also working on earlier efforts, including BOXR1030, its next-gen CAR-T program for solid tumors expressing GPC3 and based on its so-called BOXR platform “that aims to enhance the fitness of T cells in the hostile tumor microenvironment,” according to the Prague-based company.

Last month, Jessie Jackson’s friends and family sang her happy birthday a little early. Jessie doesn’t turn 30 until Dec. 12, but for the past five years on the anniversary of her diagnosis, her parents have hosted a fundraiser. They weren’t taking any chances.